

Rami S. Komrokji, MD

Professor of Medicine and Oncologic Sciences
University of South Florida College of Medicine
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

I'm Dr. Rami Komrokji from Moffitt Cancer Center answering the following question related to myeloproliferative neoplasms.

There is some data about tagraxofusp-erzs being approved last year for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), but can you tell me how it is used in the treatment of myelofibrosis and what is the connection between BPDCN and myelofibrosis?

There is really not much connection between BPDCN and myelofibrosis. BPDCN can happen in patients with myeloid neoplasms, but the target for the treatment, which is a receptor on the cell called CD123 is also present in myelofibrosis on stem cells. There had been preliminary studies looking at the drug in treatment for myelofibrosis after observing a failure, that had been reported at the past EHA meeting and there will be a follow-up at the upcoming American Society of Hematology meeting. The preliminary data suggests some responses including spleen reduction and spleen response.